Navarro Roge, Pino Ander, Martínez-Andrés Asunción, Garrigós Eva, Sánchez M Leticia, Gallego Estefanía, Anitua Eduardo
Centro Dermatológico Estético, Alicante, Spain.
BTI Biotechnology Institute, Vitoria, Spain.
J Cosmet Dermatol. 2020 Oct;19(10):2616-2626. doi: 10.1111/jocd.13661. Epub 2020 Sep 4.
Skin suffers progressive decrement. An endogenous regenerative technology has been developed that has the versatility to provide an autologous injectable gel (Endoret-Gel) or a liquid plasma rich in growth factors (PRGF) based on the patient´s own platelet-rich plasma.
To compare the efficacy of the combined therapy with Endoret-Gel and PRGF versus Endoret-Gel alone in the management of facial rejuvenation.
Twenty clinically diagnosed patients with aged skin received either Endoret-Gel monotherapy or Endoret-Gel + PRGF combined therapy. Patients underwent three sessions at one-month intervals and were clinically assessed for six months. Corneometry, sebumetry, and high-resolution topographic analysis were carried out. Patient self-assessment questionnaires and clinical improvement scores were also performed.
The combined therapy showed to promote a higher hydration index. These results were also significant for spot improvement at three months, while conversely, monotherapy with Endoret-Gel demonstrated higher UV spot improvement. A significant decrease of sebum production and wrinkle development was observed for both treatment groups. Red areas also improved in a similar way at the end of the follow-up period. After Endoret-Gel or Endoret-Gel + PRGF therapy, 30% and 70% of patients referred to be very satisfied, respectively. Accordingly, 40% and 80% showed a "very improved" esthetic performance. None of the patients reported a negative change and no adverse events were recorded.
Both Endoret-Gel monotherapy and the combined treatment with PRGF were shown to promote facial rejuvenation and to palliate the age-related cutaneous atrophy. The combined therapy may exert a synergistic effect that addresses both skin quality improvement and soft tissue restoration in a shorter period.
皮肤会逐渐衰退。现已开发出一种内源性再生技术，该技术具有多种用途，可根据患者自身的富含血小板血浆提供自体可注射凝胶（Endoret凝胶）或富含生长因子的液体血浆（PRGF）。
比较Endoret凝胶和PRGF联合治疗与单独使用Endoret凝胶治疗面部年轻化的疗效。
20名临床诊断为皮肤老化的患者接受了Endoret凝胶单一疗法或Endoret凝胶+PRGF联合疗法。患者每隔一个月进行三次治疗，并进行为期六个月的临床评估。进行了角质层水合度测量、皮脂分泌量测量和高分辨率地形分析。还进行了患者自我评估问卷和临床改善评分。
联合治疗显示可提高更高的水合指数。这些结果在三个月时对于斑点改善也很显著，而相反，Endoret凝胶单一疗法显示出更高的紫外线斑点改善效果。两个治疗组的皮脂分泌和皱纹形成均显著减少。在随访期结束时，红色区域也以类似方式得到改善。接受Endoret凝胶或Endoret凝胶+PRGF治疗后，分别有30%和70%的患者表示非常满意。相应地，40%和80%的患者表现出“非常改善”的美学效果。没有患者报告有负面变化，也没有记录到不良事件。
Endoret凝胶单一疗法和与PRGF的联合治疗均显示可促进面部年轻化并缓解与年龄相关的皮肤萎缩。联合治疗可能发挥协同作用，在更短的时间内改善皮肤质量和恢复软组织。
